Section Arrow
AVBP.NASDAQ
- ArriVent BioPharma
Quotes are at least 15-min delayed:2024/05/16 11:42 EDT
Last
 19.685
+0.185 (+0.95%)
Day High 
19.73 
Prev. Close
19.5 
1-M High
19.55 
Volume 
15.88K 
Bid
19.63
Ask
19.75
Day Low
19.3 
Open
19.43 
1-M Low
14.35 
Market Cap 
653.13M 
Currency USD 
P/E -- 
%Yield
10-SMA 17.75 
20-SMA 16.8 
50-SMA 17.64 
52-W High 25.95 
52-W Low 14.35 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.23/-2.65
Enterprise Value
653.31M
Balance Sheet
Book Value Per Share
9.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1+0.0223+28.70%-- 
DNAGinkgo Bioworks Holdings0.83025-0.00885-1.05%-- 
JAGXJaguar Health0.265495+0.010395+4.07%-- 
NVAXNovavax13.008+0.108+0.84%-- 
NBYNovaBay Pharmaceuticals0.1031-0.0014-1.34%-- 
Quotes are at least 15-min delayed:2024/05/16 11:42 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.